Micropos Medical (MPOS) Q2 2026 earnings summary

Executive summary

• Net sales for Jan–Jun 2026 were 1,593 Tkr, down from 5,979 Tkr year-over-year.

• Result after financial items was -16,458 Tkr compared to -9,803 Tkr year-over-year.

• The quarter saw high activity, new installations, and continued international expansion, especially in Spain and the US.

• NHS England adopted SBRT as standard for localized prostate cancer, increasing relevance for Raypilot System.

• A new share issue raised 24.5 Mkr after costs, supporting market expansion.

Financial highlights

• Net sales for Q2 2026 were 1,108 Tkr, down from 3,349 Tkr in Q2 2025.

• Result after financial items for Q2 was -9,514 Tkr (Q2 2025: -4,277 Tkr).

• Cash flow for the period was 7,517 Tkr (13,104 Tkr year-over-year).

• Equity at period end was 21,805 Tkr (25,591 Tkr year-over-year).

• Solid equity ratio at 80% (83% year-over-year).

Outlook and guidance

• Market trends favor shorter, more precise radiotherapy, supporting future growth.

• NHS England’s adoption of SBRT is expected to drive demand.

• Ongoing studies and clinical results support broader adoption of Raypilot System.